Stocks · Healthcare · Biotechnology
MacroGenics, Inc. MGNX
$3.58 -0.56% Close, Oct 2, 2026 · NASDAQ · Market cap $227.6M
High risk
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -24.3% from -47.6% a year earlier.
- Over the past year the stock returned +110.6%, ahead of the S&P 500 by 95.5 percentage points.
- The stock is in an uptrend: above its 200-day average for 190 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 33%
- Revenue growth, 3-year CAGRBottom 23%
- Revenue growth accelerationBottom 44%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 35%
- Gross marginBottom 34%
- Operating marginBottom 41%
- Accruals (lower is better)Bottom 5%
- Interest coverBottom 48%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 46%
- Free-cash-flow yieldBottom 17%
- EBITDA / enterprise valueBottom 11%
- Sales / enterprise valueTop 8%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 9%
- 6-month returnTop 42%
- 1-year return vs S&P 500Top 13%
- Distance from 52-week highTop 46%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 20%
- Upside to consensus price targetTop 47%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 36%
- Maximum drawdown, 3 yearsBottom 5%
- Beta vs S&P 500 (lower is better)Bottom 15%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 3.1% | 2.3% | ↓ |
| Gross margin | 59.8% | 50.4% | ↓ |
| Operating margin | -47.6% | -24.3% | ↑ |
| FCF margin | -45.5% | -39.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 2.3% | 3.1% | ↓ | Bottom 33% |
| Gross margin | 50.4% | 59.8% | ↓ | Bottom 34% |
| Operating margin | -24.3% | -47.6% | ↑ | Bottom 41% |
| Net margin | -8.7% | -22.2% | ↑ | — |
| Free-cash-flow margin | -39.1% | -45.5% | ↑ | — |
| Return on invested capital | -2.4% | — | Top 35% | |
| Revenue growth, 3-year CAGR | -0.1% | — | Bottom 23% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 14.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 6.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +1048.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -2.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.11%
- Shareholder yield
- -0.11%
- Share count change, 1 year
- +0.7%
- Share count change, 3-year CAGR
- +0.7%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 14, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -0.7%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $6.00
- Target vs current price
- +67.6%
- Analysts with a rating
- 22
- Share rating Buy or Strong Buy
- 55%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +498.2% | +1.5% | +3.7% | -1.2% | — |
| May 13, 2026 | -1.8% | -2.0% | +28.4% | +9.9% | +14.8% |
| Mar 9, 2026 | +47.6% | +5.8% | +34.5% | +42.6% | +81.6% |
| Nov 12, 2025 | +156.3% | -3.3% | +1.3% | -7.9% | +18.4% |
| Aug 14, 2025 | +3.4% | -2.4% | -10.2% | -0.6% | -18.1% |
| May 13, 2025 | -6.6% | -3.1% | +0.0% | +11.9% | +1.3% |
| Mar 20, 2025 | -8.7% | -3.7% | -28.4% | -45.9% | -30.3% |
| Nov 5, 2024 | +328.6% | +1.9% | +18.6% | -7.0% | -23.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | $0.31 | -$0.08 | +498.2% | $32.8M |
| May 13, 2026 | -$0.58 | -$0.57 | -1.8% | $20.8M |
| Mar 9, 2026 | -$0.22 | -$0.42 | +47.6% | $41.2M |
| Nov 12, 2025 | $0.27 | -$0.48 | +156.3% | $72.8M |
| Aug 14, 2025 | -$0.57 | -$0.59 | +3.4% | $22.2M |
| May 13, 2025 | -$0.65 | -$0.61 | -6.6% | $13.2M |
| Mar 20, 2025 | -$0.25 | -$0.23 | -8.7% | $17.7M |
| Nov 5, 2024 | $0.90 | $0.21 | +328.6% | $110.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 0.89× | — | — | Top 8% |
| Free-cash-flow yield | -28.80% | — | — | Bottom 17% |
| Earnings yield | -6.15% | — | — | Top 46% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 190
- 50-day average slope (20 days)
- -4.9%
- 200-day average slope (20 days)
- +8.5%
- Distance from 50-day average
- -10.5%
- Distance from 200-day average
- +9.6%
- RSI (14)
- 38.4
- Relative volume
- 1.74×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 64.2%
- Volatility vs own 5-year history
- 20th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.94
- Correlation with S&P 500
- 0.33
- Current drawdown from 1-year high
- -26.3%
- Maximum drawdown, 3 years
- -95.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 29, 2021 | Apr 4, 2025 | -97.0% | 988 days | Not yet recovered |
| Oct 5, 2020 | Feb 18, 2021 | -27.0% | 93 days | 11 days (Mar 5, 2021) |
| Mar 26, 2021 | Apr 13, 2021 | -10.9% | 11 days | 5 days (Apr 20, 2021) |
| Mar 22, 2021 | Mar 24, 2021 | -10.7% | 2 days | 1 days (Mar 25, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $227.6M
- EPS, diluted (TTM)
- -$0.22
- Revenue (TTM)
- $167.7M
- 52-week range
- $1.29 – $5.08
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $75.6M | $150.0M | $57.2M | $148.3M | $149.5M |
| Gross profit | $73.0M | $142.6M | $49.0M | $136.0M | $106.3M |
| Operating income | -$202.8M | -$121.4M | -$168.2M | -$110.6M | -$72.8M |
| Net income | -$202.1M | -$119.8M | -$9.1M | -$67.0M | -$74.6M |
| EPS (diluted) | -$3.37 | -$1.95 | -$0.15 | -$1.07 | -$1.18 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $110.7M | $17.7M | $13.2M | $22.2M | $72.8M | $41.2M | $20.8M | $32.8M |
| Net income | $56.3M | -$15.4M | -$41.0M | -$36.3M | $16.8M | -$14.2M | -$36.8M | $19.5M |
| EPS (diluted) | $0.90 | -$0.25 | -$0.65 | -$0.57 | $0.27 | -$0.22 | -$0.58 | $0.31 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$143.8M | -$87.0M | -$78.2M | -$68.4M | -$81.0M |
| Capital expenditure | -$6.2M | -$3.6M | -$1.8M | -$3.7M | -$1.9M |
| Free cash flow | -$150.0M | -$90.6M | -$80.0M | -$72.1M | -$83.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $117.8M | $1.1M | $1.2M | $3.4M | $129,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $173.3M
- Total assets
- $345.4M
- Total liabilities
- $302.5M
- Total debt
- $35.1M
- Net debt
- -$78.8M
- Shareholders’ equity
- $42.9M
As of Jun 30, 2026 (filed Aug 14, 2026).
Short interest
- Shares sold short
- 7,032,428
- Days to cover
- 15.73
- Change vs previous report
- -1.3%
FINRA short interest, settlement date Sep 15, 2026.